Loading…

Lipidomic profiling of plasma and urine from patients with Gaucher disease during enzyme replacement therapy by nanoflow liquid chromatography–tandem mass spectrometry

•Plasma and urinary lipids from Gaucher disease patients were profiled.•Changes of lipids in GD patients before and after enzyme replacement therapy were investigated.•20 plasma and 10 urinary lipids showed significant differences compared to controls.•Enzyme replacement therapy decreased overall le...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Chromatography A 2015-02, Vol.1381, p.132-139
Main Authors: Byeon, Seul Kee, Lee, Ju Yong, Lee, Jin-Sung, Moon, Myeong Hee
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c465t-766a0b2d6200fa5125a9eac507e547fd1fc74b9bb186d977399c512b1d12c6a23
cites cdi_FETCH-LOGICAL-c465t-766a0b2d6200fa5125a9eac507e547fd1fc74b9bb186d977399c512b1d12c6a23
container_end_page 139
container_issue
container_start_page 132
container_title Journal of Chromatography A
container_volume 1381
creator Byeon, Seul Kee
Lee, Ju Yong
Lee, Jin-Sung
Moon, Myeong Hee
description •Plasma and urinary lipids from Gaucher disease patients were profiled.•Changes of lipids in GD patients before and after enzyme replacement therapy were investigated.•20 plasma and 10 urinary lipids showed significant differences compared to controls.•Enzyme replacement therapy decreased overall levels of five MHC's in patients. Gaucher disease (GD) is a rare genetic disorder that arises from lipid species, especially monohexosylceramide (MHC), accumulating in different organs. GD results from a β-glucocerebrosidase deficiency, causing metabolic or neurologic complications. This study comprehensively profiled lipids from patients and healthy controls to discover active lipid species related to GD. Most studies have evaluated lipids from one type of biological sample, such as plasma, urine, or spinal fluid, which are the main sources of lipids in human bodies. The purpose of this study, however, was to collect and assess both plasma and urine samples from a group of individuals, explore the lipids, and select characteristic species that show significant differences between controls and patients from the two sources. Also, the response of lipids to enzyme replacement therapy (ERT), which is targeted to reduce excessive lipid accumulation within lysosomes, was investigated by obtaining plasma and urine from patients after receiving the therapy. Most lipid species were found in both plasma and urine but their concentrations differed, and some species were found in either plasma or urine only. Out of 125 plasma and 105 urinary lipids that were identified by nLC–ESI–MS/MS, 20 plasma and 10 urinary lipids were selected as characteristic species for having average concentrations that were significantly increased or decreased in patients by greater than 2-fold. Moreover, the concentrations of most lipids that showed greater than 2-fold of difference in patients decreased after ERT indicating that these species were directly or indirectly affected by the therapy.
doi_str_mv 10.1016/j.chroma.2015.01.004
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1685779914</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0021967315000333</els_id><sourcerecordid>1685779914</sourcerecordid><originalsourceid>FETCH-LOGICAL-c465t-766a0b2d6200fa5125a9eac507e547fd1fc74b9bb186d977399c512b1d12c6a23</originalsourceid><addsrcrecordid>eNp9kbGO1DAQhlOAxHHHG1BMSbPBzib2pUFCJ7hDWonmqK2JPd71Ko5ztsMpVLwDT8Fr8SR4FWqqKeabf-afv6reclZzxsX7c61PMXisG8a7mvGasfZFdcVYw3e9kPtX1euUzoxxyWRzVf0-uNmZ4J2GOQbrRjcdIViYR0weAScDS3QTgS2iMGN2NOUEzy6f4B4XfaIIxiXCRGAu5BFo-rF6gkhFQ5MvPOSC4bzCsMKEU7BjeIbRPS3OwHZtDscCnNY_P3_lspM8eEwJ0kw6lz7luN5ULy2Oid78q9fVt8-fHu8edoev91_uPh52uhVd3kkhkA2NEQ1jFjvedNgT6o5J6lppDbdatkM_DPxWmF7Kfd_rQg3c8EYLbPbX1btNt_zjaaGUlXdJ0zjiRGFJiovbTsq-521B2w3VMaQUyao5Oo9xVZypSxrqrDZ_6pKGYlyVNMrYh22Mio3vjqJKurxVk3Gx-FUmuP8L_AX8dZ2W</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1685779914</pqid></control><display><type>article</type><title>Lipidomic profiling of plasma and urine from patients with Gaucher disease during enzyme replacement therapy by nanoflow liquid chromatography–tandem mass spectrometry</title><source>ScienceDirect Freedom Collection</source><creator>Byeon, Seul Kee ; Lee, Ju Yong ; Lee, Jin-Sung ; Moon, Myeong Hee</creator><creatorcontrib>Byeon, Seul Kee ; Lee, Ju Yong ; Lee, Jin-Sung ; Moon, Myeong Hee</creatorcontrib><description>•Plasma and urinary lipids from Gaucher disease patients were profiled.•Changes of lipids in GD patients before and after enzyme replacement therapy were investigated.•20 plasma and 10 urinary lipids showed significant differences compared to controls.•Enzyme replacement therapy decreased overall levels of five MHC's in patients. Gaucher disease (GD) is a rare genetic disorder that arises from lipid species, especially monohexosylceramide (MHC), accumulating in different organs. GD results from a β-glucocerebrosidase deficiency, causing metabolic or neurologic complications. This study comprehensively profiled lipids from patients and healthy controls to discover active lipid species related to GD. Most studies have evaluated lipids from one type of biological sample, such as plasma, urine, or spinal fluid, which are the main sources of lipids in human bodies. The purpose of this study, however, was to collect and assess both plasma and urine samples from a group of individuals, explore the lipids, and select characteristic species that show significant differences between controls and patients from the two sources. Also, the response of lipids to enzyme replacement therapy (ERT), which is targeted to reduce excessive lipid accumulation within lysosomes, was investigated by obtaining plasma and urine from patients after receiving the therapy. Most lipid species were found in both plasma and urine but their concentrations differed, and some species were found in either plasma or urine only. Out of 125 plasma and 105 urinary lipids that were identified by nLC–ESI–MS/MS, 20 plasma and 10 urinary lipids were selected as characteristic species for having average concentrations that were significantly increased or decreased in patients by greater than 2-fold. Moreover, the concentrations of most lipids that showed greater than 2-fold of difference in patients decreased after ERT indicating that these species were directly or indirectly affected by the therapy.</description><identifier>ISSN: 0021-9673</identifier><identifier>DOI: 10.1016/j.chroma.2015.01.004</identifier><language>eng</language><publisher>Elsevier B.V</publisher><subject>Chromatography ; Control equipment ; Enzyme replacement therapy ; Enzymes ; Gaucher disease ; Lipid profiling ; Lipids ; Monohexosylceramide (MHC) ; nLC–ESI–MS/MS ; Patients ; Receiving ; Therapy ; Urine</subject><ispartof>Journal of Chromatography A, 2015-02, Vol.1381, p.132-139</ispartof><rights>2015 Elsevier B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c465t-766a0b2d6200fa5125a9eac507e547fd1fc74b9bb186d977399c512b1d12c6a23</citedby><cites>FETCH-LOGICAL-c465t-766a0b2d6200fa5125a9eac507e547fd1fc74b9bb186d977399c512b1d12c6a23</cites><orcidid>0000-0002-5454-2601</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27898,27899</link.rule.ids></links><search><creatorcontrib>Byeon, Seul Kee</creatorcontrib><creatorcontrib>Lee, Ju Yong</creatorcontrib><creatorcontrib>Lee, Jin-Sung</creatorcontrib><creatorcontrib>Moon, Myeong Hee</creatorcontrib><title>Lipidomic profiling of plasma and urine from patients with Gaucher disease during enzyme replacement therapy by nanoflow liquid chromatography–tandem mass spectrometry</title><title>Journal of Chromatography A</title><description>•Plasma and urinary lipids from Gaucher disease patients were profiled.•Changes of lipids in GD patients before and after enzyme replacement therapy were investigated.•20 plasma and 10 urinary lipids showed significant differences compared to controls.•Enzyme replacement therapy decreased overall levels of five MHC's in patients. Gaucher disease (GD) is a rare genetic disorder that arises from lipid species, especially monohexosylceramide (MHC), accumulating in different organs. GD results from a β-glucocerebrosidase deficiency, causing metabolic or neurologic complications. This study comprehensively profiled lipids from patients and healthy controls to discover active lipid species related to GD. Most studies have evaluated lipids from one type of biological sample, such as plasma, urine, or spinal fluid, which are the main sources of lipids in human bodies. The purpose of this study, however, was to collect and assess both plasma and urine samples from a group of individuals, explore the lipids, and select characteristic species that show significant differences between controls and patients from the two sources. Also, the response of lipids to enzyme replacement therapy (ERT), which is targeted to reduce excessive lipid accumulation within lysosomes, was investigated by obtaining plasma and urine from patients after receiving the therapy. Most lipid species were found in both plasma and urine but their concentrations differed, and some species were found in either plasma or urine only. Out of 125 plasma and 105 urinary lipids that were identified by nLC–ESI–MS/MS, 20 plasma and 10 urinary lipids were selected as characteristic species for having average concentrations that were significantly increased or decreased in patients by greater than 2-fold. Moreover, the concentrations of most lipids that showed greater than 2-fold of difference in patients decreased after ERT indicating that these species were directly or indirectly affected by the therapy.</description><subject>Chromatography</subject><subject>Control equipment</subject><subject>Enzyme replacement therapy</subject><subject>Enzymes</subject><subject>Gaucher disease</subject><subject>Lipid profiling</subject><subject>Lipids</subject><subject>Monohexosylceramide (MHC)</subject><subject>nLC–ESI–MS/MS</subject><subject>Patients</subject><subject>Receiving</subject><subject>Therapy</subject><subject>Urine</subject><issn>0021-9673</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNp9kbGO1DAQhlOAxHHHG1BMSbPBzib2pUFCJ7hDWonmqK2JPd71Ko5ztsMpVLwDT8Fr8SR4FWqqKeabf-afv6reclZzxsX7c61PMXisG8a7mvGasfZFdcVYw3e9kPtX1euUzoxxyWRzVf0-uNmZ4J2GOQbrRjcdIViYR0weAScDS3QTgS2iMGN2NOUEzy6f4B4XfaIIxiXCRGAu5BFo-rF6gkhFQ5MvPOSC4bzCsMKEU7BjeIbRPS3OwHZtDscCnNY_P3_lspM8eEwJ0kw6lz7luN5ULy2Oid78q9fVt8-fHu8edoev91_uPh52uhVd3kkhkA2NEQ1jFjvedNgT6o5J6lppDbdatkM_DPxWmF7Kfd_rQg3c8EYLbPbX1btNt_zjaaGUlXdJ0zjiRGFJiovbTsq-521B2w3VMaQUyao5Oo9xVZypSxrqrDZ_6pKGYlyVNMrYh22Mio3vjqJKurxVk3Gx-FUmuP8L_AX8dZ2W</recordid><startdate>20150213</startdate><enddate>20150213</enddate><creator>Byeon, Seul Kee</creator><creator>Lee, Ju Yong</creator><creator>Lee, Jin-Sung</creator><creator>Moon, Myeong Hee</creator><general>Elsevier B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7U5</scope><scope>8FD</scope><scope>L7M</scope><orcidid>https://orcid.org/0000-0002-5454-2601</orcidid></search><sort><creationdate>20150213</creationdate><title>Lipidomic profiling of plasma and urine from patients with Gaucher disease during enzyme replacement therapy by nanoflow liquid chromatography–tandem mass spectrometry</title><author>Byeon, Seul Kee ; Lee, Ju Yong ; Lee, Jin-Sung ; Moon, Myeong Hee</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c465t-766a0b2d6200fa5125a9eac507e547fd1fc74b9bb186d977399c512b1d12c6a23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Chromatography</topic><topic>Control equipment</topic><topic>Enzyme replacement therapy</topic><topic>Enzymes</topic><topic>Gaucher disease</topic><topic>Lipid profiling</topic><topic>Lipids</topic><topic>Monohexosylceramide (MHC)</topic><topic>nLC–ESI–MS/MS</topic><topic>Patients</topic><topic>Receiving</topic><topic>Therapy</topic><topic>Urine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Byeon, Seul Kee</creatorcontrib><creatorcontrib>Lee, Ju Yong</creatorcontrib><creatorcontrib>Lee, Jin-Sung</creatorcontrib><creatorcontrib>Moon, Myeong Hee</creatorcontrib><collection>CrossRef</collection><collection>Solid State and Superconductivity Abstracts</collection><collection>Technology Research Database</collection><collection>Advanced Technologies Database with Aerospace</collection><jtitle>Journal of Chromatography A</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Byeon, Seul Kee</au><au>Lee, Ju Yong</au><au>Lee, Jin-Sung</au><au>Moon, Myeong Hee</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lipidomic profiling of plasma and urine from patients with Gaucher disease during enzyme replacement therapy by nanoflow liquid chromatography–tandem mass spectrometry</atitle><jtitle>Journal of Chromatography A</jtitle><date>2015-02-13</date><risdate>2015</risdate><volume>1381</volume><spage>132</spage><epage>139</epage><pages>132-139</pages><issn>0021-9673</issn><abstract>•Plasma and urinary lipids from Gaucher disease patients were profiled.•Changes of lipids in GD patients before and after enzyme replacement therapy were investigated.•20 plasma and 10 urinary lipids showed significant differences compared to controls.•Enzyme replacement therapy decreased overall levels of five MHC's in patients. Gaucher disease (GD) is a rare genetic disorder that arises from lipid species, especially monohexosylceramide (MHC), accumulating in different organs. GD results from a β-glucocerebrosidase deficiency, causing metabolic or neurologic complications. This study comprehensively profiled lipids from patients and healthy controls to discover active lipid species related to GD. Most studies have evaluated lipids from one type of biological sample, such as plasma, urine, or spinal fluid, which are the main sources of lipids in human bodies. The purpose of this study, however, was to collect and assess both plasma and urine samples from a group of individuals, explore the lipids, and select characteristic species that show significant differences between controls and patients from the two sources. Also, the response of lipids to enzyme replacement therapy (ERT), which is targeted to reduce excessive lipid accumulation within lysosomes, was investigated by obtaining plasma and urine from patients after receiving the therapy. Most lipid species were found in both plasma and urine but their concentrations differed, and some species were found in either plasma or urine only. Out of 125 plasma and 105 urinary lipids that were identified by nLC–ESI–MS/MS, 20 plasma and 10 urinary lipids were selected as characteristic species for having average concentrations that were significantly increased or decreased in patients by greater than 2-fold. Moreover, the concentrations of most lipids that showed greater than 2-fold of difference in patients decreased after ERT indicating that these species were directly or indirectly affected by the therapy.</abstract><pub>Elsevier B.V</pub><doi>10.1016/j.chroma.2015.01.004</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-5454-2601</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0021-9673
ispartof Journal of Chromatography A, 2015-02, Vol.1381, p.132-139
issn 0021-9673
language eng
recordid cdi_proquest_miscellaneous_1685779914
source ScienceDirect Freedom Collection
subjects Chromatography
Control equipment
Enzyme replacement therapy
Enzymes
Gaucher disease
Lipid profiling
Lipids
Monohexosylceramide (MHC)
nLC–ESI–MS/MS
Patients
Receiving
Therapy
Urine
title Lipidomic profiling of plasma and urine from patients with Gaucher disease during enzyme replacement therapy by nanoflow liquid chromatography–tandem mass spectrometry
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-03-04T20%3A40%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lipidomic%20profiling%20of%20plasma%20and%20urine%20from%20patients%20with%20Gaucher%20disease%20during%20enzyme%20replacement%20therapy%20by%20nanoflow%20liquid%20chromatography%E2%80%93tandem%20mass%20spectrometry&rft.jtitle=Journal%20of%20Chromatography%20A&rft.au=Byeon,%20Seul%20Kee&rft.date=2015-02-13&rft.volume=1381&rft.spage=132&rft.epage=139&rft.pages=132-139&rft.issn=0021-9673&rft_id=info:doi/10.1016/j.chroma.2015.01.004&rft_dat=%3Cproquest_cross%3E1685779914%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c465t-766a0b2d6200fa5125a9eac507e547fd1fc74b9bb186d977399c512b1d12c6a23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1685779914&rft_id=info:pmid/&rfr_iscdi=true